Outcomes of haploidentical bone marrow transplantation in patients with severe aplastic anemia-II that progressed from non-severe acquired aplastic anemia.
10.1007/s11684-020-0807-4
- Author:
Hongchen LIU
1
;
Xiaoli ZHENG
2
;
Chengtao ZHANG
1
;
Jiajun XIE
1
;
Beibei GAO
1
;
Jing SHAO
1
;
Yan YANG
3
;
Hengxiang WANG
4
;
Jinsong YAN
5
Author Information
1. Department of Hematology, Liaoning Medical Center for Hematopoietic Stem Cell Transplantation, Dalian Key Laboratory of Hematology, Liaoning Key Laboratory of Hematopoietic Stem Cell Transplantation and Translational Medicine, Diamond Bay Institute of Hematology, the Second Hospital of Dalian Medical University, Dalian, 116027, China.
2. Department of Hematology, Air Force Medical Center, PLA, Beijing, 100142, China.
3. Department of Hematology, Liaoning Medical Center for Hematopoietic Stem Cell Transplantation, Dalian Key Laboratory of Hematology, Liaoning Key Laboratory of Hematopoietic Stem Cell Transplantation and Translational Medicine, Diamond Bay Institute of Hematology, the Second Hospital of Dalian Medical University, Dalian, 116027, China. yangyanxyfs@sina.com.
4. Department of Hematology, Air Force Medical Center, PLA, Beijing, 100142, China. wanghengxiang123@aliyun.com.
5. Department of Hematology, Liaoning Medical Center for Hematopoietic Stem Cell Transplantation, Dalian Key Laboratory of Hematology, Liaoning Key Laboratory of Hematopoietic Stem Cell Transplantation and Translational Medicine, Diamond Bay Institute of Hematology, the Second Hospital of Dalian Medical University, Dalian, 116027, China. yanjsdmu@126.com.
- Publication Type:Journal Article
- Keywords:
haploidentical bone marrow transplantation;
non-severe acquired aplastic anemia;
outcomes;
severe aplastic anemia
- MeSH:
Anemia, Aplastic/therapy*;
Bone Marrow Transplantation;
Graft vs Host Disease;
HLA Antigens;
Hematopoietic Stem Cell Transplantation;
Humans;
Transplantation Conditioning
- From:
Frontiers of Medicine
2021;15(5):718-727
- CountryChina
- Language:English
-
Abstract:
Severe aplastic anemia II (SAA-II) progresses from non-severe aplastic anemia (NSAA). The unavailability of efficacious treatment has prompted the need for haploidentical bone marrow transplantation (haplo-BMT) in patients lacking a human leukocyte antigen (HLA)-matched donor. This study aimed to investigate the efficacy of haplo-BMT for patients with SAA-II. Twenty-two patients were included and followed up, and FLU/BU/CY/ATG was used as conditioning regimen. Among these patients, 21 were successfully engrafted, 19 of whom survived after haplo-BMT. Four patients experienced grade II-IV aGvHD, including two with grade III-IV aGvHD. Six patients experienced chronic GvHD, among whom four were mild and two were moderate. Twelve patients experienced infections during BMT. One was diagnosed with post-transplant lymphoproliferative disorder and one with probable EBV disease, and both recovered after rituximab infusion. Haplo-BMT achieved 3-year overall survival and disease-free survival rate of 86.4% ± 0.73% after a median follow-up of 42 months, indicating its effectiveness as a salvage therapy. These promising outcomes may support haplo-BMT as an alternative treatment strategy for patients with SAA-II lacking HLA-matched donors.
